ZA913509B - Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor - Google Patents

Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor

Info

Publication number: ZA913509B
Authority: ZA; South Africa
Prior art keywords: combination; stabilizing; ace inhibitor; cholesterol lowering; preventing
Prior art date: 1990-05-15

Application number

ZA913509A

Other languages

English (en)

Inventor

James L Bergey

L Bergey James

Werner Tshcollar

Tshcollar Werner

Cary S Yonce

S Yonce Cary

James C Kawano

C Kawano James

Original Assignee

Squibb & Sons Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-15

Filing date

1991-05-08

Publication date

1992-02-26

1991-05-08 Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc

1992-02-26 Publication of ZA913509B publication Critical patent/ZA913509B/xx

Links

239000005541 ACE inhibitor Substances 0.000 title abstract 2
201000001320 Atherosclerosis Diseases 0.000 title abstract 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title abstract 2
239000003529 anticholesteremic agent Substances 0.000 title abstract 2
230000000087 stabilizing effect Effects 0.000 title 1
206010020772 Hypertension Diseases 0.000 abstract 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
230000003143 atherosclerotic effect Effects 0.000 abstract 1
229960000830 captopril Drugs 0.000 abstract 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 1
230000001631 hypertensive effect Effects 0.000 abstract 1
230000003902 lesion Effects 0.000 abstract 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
229960002965 pravastatin Drugs 0.000 abstract 1
125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
229960002769 zofenopril Drugs 0.000 abstract 1
IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA913509A 1990-05-15 1991-05-08 Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor ZA913509B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US52426690A	1990-05-15	1990-05-15

Publications (1)

Publication Number	Publication Date
ZA913509B true ZA913509B (en)	1992-02-26

Family

ID=24088484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA913509A ZA913509B (en)	1990-05-15	1991-05-08	Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor

Country Status (15)

Country	Link
EP (1)	EP0457514B1 (de)
JP (1)	JPH04226921A (de)
KR (1)	KR100200467B1 (de)
AT (1)	ATE141514T1 (de)
AU (1)	AU651579B2 (de)
CA (1)	CA2040865C (de)
DE (1)	DE69121464T2 (de)
DK (1)	DK0457514T3 (de)
ES (1)	ES2090244T3 (de)
GR (1)	GR3021703T3 (de)
HU (1)	HU212102B (de)
IE (1)	IE77637B1 (de)
NZ (1)	NZ237929A (de)
PT (1)	PT97660B (de)
ZA (1)	ZA913509B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5157025A (en) *	1991-04-01	1992-10-20	E. R. Squibb & Sons, Inc.	Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
AU3473193A (en) *	1992-01-17	1993-08-03	Procter & Gamble Company, The	Treatment for atherosclerosis
AU1095695A (en) *	1993-11-09	1995-05-29	Brigham And Women's Hospital	Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
DE4402379C2 (de) *	1994-01-27	1997-09-25	Lohmann Therapie Syst Lts	Orale Arzneiform mit sauren Wirkstoffen und Verfahren zu ihrer Herstellung
CA2186606A1 (en) *	1994-03-29	1995-10-05	Edward B. Nelson	Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
PL189066B1 (pl) *	1996-04-05	2005-06-30	Takeda Pharmaceutical	Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz stosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II
EP1514543A1 (de)	1997-08-29	2005-03-16	Pfizer Inc.	Kombinationstherapie, enthaltend Atorvastatin und blutdrucksenkendes Mittel
SI20305A (sl)	1999-08-06	2001-02-28	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Kristali natrijeve soli pravastatina
AU2007200367B2 (en) *	1999-02-06	2010-04-08	Astrazeneca Ab	Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
US6172441B1 (en)	1999-06-28	2001-01-09	Visteon Global Technologies, Inc.	Rotor assembly
PL353199A1 (en)	1999-08-30	2003-11-03	Aventis Pharma Deutschland Gmbh	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en)	2001-01-26	2004-01-04	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es)	2001-01-26	2004-06-02	Schering Corp	Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
US6576256B2 (en)	2001-08-28	2003-06-10	The Brigham And Women's Hospital, Inc.	Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en)	2001-08-28	2003-12-30	Longwood Pharmaceutical Research, Inc.	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
MXPA04002573A (es)	2001-09-21	2004-06-18	Schering Corp	Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
AU2003227691B2 (en) *	2002-05-03	2008-05-15	Hexal Ag	Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
AR040588A1 (es)	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja)	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601668B1 (de)	2003-03-07	2008-08-27	Schering Corporation	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CA2517572C (en)	2003-03-07	2011-12-13	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004085448A2 (en) *	2003-03-19	2004-10-07	Genzyme Corporation	Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
EP2389178A4 (de) *	2008-12-01	2012-06-06	Invasc Therapeutic Inc	Zusammensetzungen mit hemmern des renin-angiotensin-aldosteron-systems und liponsäureverbindungen sowie ihre verwendung zur behandlung von renin-angiotensin-aldosteron-systembedingten erkrankungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3536687A1 (de) *	1985-10-15	1987-04-16	Hoechst Ag	Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit

1991
- 1991-04-19 CA CA002040865A patent/CA2040865C/en not_active Expired - Lifetime
- 1991-04-24 NZ NZ237929A patent/NZ237929A/en unknown
- 1991-04-26 AU AU76270/91A patent/AU651579B2/en not_active Expired
- 1991-04-29 IE IE143191A patent/IE77637B1/en not_active IP Right Cessation
- 1991-05-08 ZA ZA913509A patent/ZA913509B/xx unknown
- 1991-05-10 AT AT91304232T patent/ATE141514T1/de not_active IP Right Cessation
- 1991-05-10 ES ES91304232T patent/ES2090244T3/es not_active Expired - Lifetime
- 1991-05-10 DK DK91304232.1T patent/DK0457514T3/da active
- 1991-05-10 DE DE69121464T patent/DE69121464T2/de not_active Expired - Lifetime
- 1991-05-10 EP EP91304232A patent/EP0457514B1/de not_active Expired - Lifetime
- 1991-05-14 KR KR1019910007749A patent/KR100200467B1/ko not_active Expired - Lifetime
- 1991-05-14 HU HU911620A patent/HU212102B/hu unknown
- 1991-05-14 PT PT97660A patent/PT97660B/pt not_active IP Right Cessation
- 1991-05-15 JP JP3110268A patent/JPH04226921A/ja not_active Withdrawn
1996
- 1996-11-19 GR GR960403096T patent/GR3021703T3/el unknown

Also Published As

Publication number	Publication date
NZ237929A (en)	1997-06-24
HU212102B (en)	1996-02-28
PT97660A (pt)	1992-02-28
ES2090244T3 (es)	1996-10-16
IE911431A1 (en)	1991-11-20
KR910019614A (ko)	1991-12-19
DK0457514T3 (da)	1996-09-16
ATE141514T1 (de)	1996-09-15
JPH04226921A (ja)	1992-08-17
IE77637B1 (en)	1997-12-31
GR3021703T3 (en)	1997-02-28
AU7627091A (en)	1991-11-21
CA2040865A1 (en)	1991-11-16
DE69121464D1 (de)	1996-09-26
HU911620D0 (en)	1991-11-28
AU651579B2 (en)	1994-07-28
DE69121464T2 (de)	1997-03-27
HUT57993A (en)	1992-01-28
EP0457514B1 (de)	1996-08-21
KR100200467B1 (ko)	1999-06-15
PT97660B (pt)	1998-09-30
EP0457514A1 (de)	1991-11-21
CA2040865C (en)	2002-07-23

Publication	Publication Date	Title
ZA913509B (en)	1992-02-26	Method for preventing,stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
GR3035526T3 (en)	2001-06-29	Retroviral protease inhibitors.
AU5074196A (en)	1996-10-31	Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
GR3026222T3 (en)	1998-05-29	Novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
AU7939787A (en)	1988-04-21	Drug compositions stabilized against oxidation
KR900009079A (ko)	1990-07-02	비스(3,5-디-tert-부틸-4-히드록시페닐티오)메탄 함유 콜레스테롤 저하제겸 아테롬성 동맥 경화증 치료제
SG54138A1 (en)	1998-11-16	Dual action inhibitors
ZA943896B (en)	1995-12-04	Pharmaceutical agents for treatment of emesis
DK0458287T3 (da)	1996-10-07	Anvendelse af magnesium-pyridoxal-5-phosphat-glutaminat til forebyggelse af sygdomme forårsaget af vaskulære læsioner
EP0455448A3 (en)	1992-07-08	Treatment of pancreatic disease with 15-keto-prostaglandin compounds
EP0631760A3 (de)	1995-09-13	Chirurgisches Abdecktuch mit verbesserter Konstruktion für kritisches Gebiet.
AU7854094A (en)	1995-05-01	Use of amiodarone for the treatment of heart failure
EP0381074A3 (de)	1992-05-20	Verfahren zur Diäterleichterung unter Verwendung eines ACE-Inhibitors
AU7719491A (en)	1991-11-28	Therapeutic compound
ZA971715B (en)	1998-08-27	Method of reducing tissue damage associated with ischemia
IL132504A0 (en)	2001-03-19	Methods for reducing fibrinogen
AU1067795A (en)	1995-06-13	Use of lithium compounds in the treatment and prevention of alzheimer's disease
FR2708181B3 (fr)	1995-07-21	Elévateur de lit table élévatrice.
FR2693358B1 (fr)	1994-08-26	Barrière de sécurité éclipsable pour lit d'hôpital.
ZA93744B (en)	1993-09-07	Phosphonoxy and carbonate derivatives of taxol.
IL108109A0 (en)	1994-04-12	A composition of cuznsod or mnsod for the treatment of viral lung infections
FR2714717B1 (fr)	1996-03-22	Procédé d'oxydation des imbrûlés de matières hydrocarbonées.
IS3900A (is)	1993-03-02	Nálar fyrir skurðlækna
GB9309871D0 (en)	1993-06-23	Surgical operating tables